ArticleScientific reports2025
Quality evaluation of Capitatae Fructus from different geographical regions in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Capitatae Fructus (CF), an ethnomedicinal resource with both edible and medicinal values in Southwest China, has an incomplete quality evaluation system, and the regulatory mechanisms of environmental factors on its bioactive component accumulation remain unclear. In this study, 37 CF batches from 6 producing areas in Sichuan and Yunnan Provinces were analyzed. High-performance liquid chromatography (HPLC) was used to establish a fingerprint with good precision and reproducibility and conduct multi-component quantitative analysis, combined with hierarchical cluster analysis (HCA), Correlation analysis, principal component analysis (PCA), and hierarchical partitioning (HP) to investigate CF's chemical characteristics and environmental regulation patterns. Results showed an HPLC fingerprint of CF was successfully constructed, with 15 common peaks matched and 5 key bioactive compounds (gallic acid, hyperoside, isoquercitrin, quercitrin, quercetin) identified. HCA classified the samples into two distinct clusters: the first cluster covers low-, medium-, and high-altitude regions, among which the gallic acid contents (L26, L27) and quercetin content (L28) from Miyi County (low-altitude area) are higher than those of other sample batches. In contrast, the second cluster, concentrated in medium-altitude regions, generally exhibits lower contents of key components. Results from PCA show that sample L28 (Miyi County, low-altitude area) has the highest comprehensive score, which further confirms this altitude-related distribution characteristic of the compounds in CF. Correlation analysis was conducted to examine relationships between the 5 key compounds, showing that gallic acid was significantly positively correlated with hyperoside (r = 0.46, P < 0.01), and hyperoside was extremely significantly positively correlated with isoquercitrin (r = 0.91, P < 0.001). HP analysis was used to eliminate multicollinearity among environmental factors, confirming annual total solar radiation and annual cumulative ultraviolet radiation as core regulatory factors for CF component accumulation. Among the 5 compounds, gallic acid and hyperoside exhibited the highest sensitivity to environmental changes (R² = 0.76 and 0.71, respectively). Based on the above findings, Miyi County was identified as a high-quality producing area for CF, with gallic acid and hyperoside confirmed as the core quality indicators of CF. East longitude was determined to be the main environmental factor affecting CF component accumulation, while Annual Total Solar Radiation, Annual Cumulative Ultraviolet Radiation, and Annual Total Solar Radiation Difference were the synergistic driving factors. This study initially established a quality evaluation system for CF, providing support for its standardized development and sustainable utilization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.